PRESSEMITTEILUNGEN

——————————————————————————–
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
——————————————————————————–

Strategic management decisions

Vienna (Austria), June 8, 2010 (euro adhoc) – Intercell AG (VSE: ICLL) today announced the closing of the acquisition of Cytos’ platform technology for monoclonal antibody discovery. On May 6, 2010 Intercell had announced the intent to acquire that technology, which is based on expression cloning of monoclonal antibodies from human B-cells, for EUR 15m.

The antibody technology complements Intercell’s technology platforms and opens novel medically and commercially relevant applications for Intercell’s Antigen Identification Program (AIP®).

end of announcement euro adhoc
——————————————————————————–

Further inquiry note:

Intercell AG
Lucia Malfent
Vice President, Global Head Corporate Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market

Trackback URL

Adhoc, Antibody Technology, Antigen, B Cells, Cloning, Corporate Communications, Corporate News, Global Head, Intercell Ag, Isin, Management Decisions, Monoclonal Antibodies, Monoclonal Antibody, Platform Technology, Relevant Applications, Strategic Management, Technology Platform, Technology Platforms, Vienna Austria, Vse